Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers
Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers
Sponsor: UConn Health
Terminated
Study was terminated early due to low enrollment numbers.
Other terminated trials from UConn Health
Other Atrial Fibrillation trials with similar outcome
A observational or N/A phase clinical study on Atrial Fibrillation, this trial is terminated or withdrawn. The trial is conducted by UConn Health and has accumulated 12 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 7 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
May 2017 — Aug 2017 [monthly]
Terminated NA
-
Apr 2017 — May 2017 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jan 2017 — Apr 2017 [monthly]
Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UConn Health
For direct contact, visit the study record on ClinicalTrials.gov .